Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches

被引:0
|
作者
Thomas Kelleher
Alexandra Thiry
Richard Wilber
Anne Cross
机构
[1] Dept. 703,Pharmaceutical Research Institute
[2] Bristol-Myers Squibb Company,undefined
关键词
Missing data; HIV; Clinical trials; Regulatory guidance;
D O I
暂无
中图分类号
学科分类号
摘要
Efficacy in HIV clinical trials is measured by changes in HIV RNA levels over time as well as the proportion of subjects with HIV RNA levels below an assay’s threshold of reliable quantification at a single time point. Missing data arise naturally due to missed visits and premature discontinuations of treatment. The available data are then analyzed using repeated measures models and univariate comparisons of proportions, assuming missing data occur at random or considering missing values as treatment failures (worst case scenario). These and other methods recently proposed by regulatory authorities are presented along with alternative approaches. Advantages and disadvantages of each method are discussed. Data from a recent comparison of ’ standard-of-care’ triple combination regimens are used for illustration.
引用
收藏
页码:1363 / 1371
页数:8
相关论文
共 50 条